New developments in immunotherapies for food allergy.

about

The Use of Omalizumab in Food Oral Immunotherapy.Pru p 3-Epitope-based sublingual immunotherapy in a murine model for the treatment of peach allergy.

P2860

Q38954322-4912918B-7F7A-4C64-A0FB-C65660B90C2B Q50957303-36D0B71F-8225-48CB-8134-7A93BD7123C6

P2860

New developments in immunotherapies for food allergy.

Item

http://www.wikidata.org/entity/Q38565704

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

New developments in immunotherapies for food allergy.

@en

type

Item

label

New developments in immunotherapies for food allergy.

@en

prefLabel

New developments in immunotherapies for food allergy.

@en

P1476

New developments in immunotherapies for food allergy.

@en

P2093

Anne Marie Singh

http://www.w3.org/2001/XMLSchema#string

Krishan Dilip Chhiba

http://www.w3.org/2001/XMLSchema#string

Paul J Bryce

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of anti-IgE therapy in patients with peanut allergy

State of the art on food allergen immunotherapy: oral, sublingual, and epicutaneous

A phase II, randomized, double‑blind, parallel‑group, placebo‑controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy

Accelerated dissociation of IgE-FcεRI complexes by disruptive inhibitors actively desensitizes allergic effector cells.

Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3).

National prevalence and risk factors for food allergy and relationship to asthma: results from the National Health and Nutrition Examination Survey 2005-2006.

Oral and sublingual immunotherapy for food allergy: current progress and future directions.

Safety and feasibility of oral immunotherapy to multiple allergens for food allergy.

CD4+CD25+ regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction.

Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial.

P304

913-922

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/IMT.15.55

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-08-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26268849

http://www.w3.org/2001/XMLSchema#string

New developments in immunotherapies for food allergy.

about

P2860

P2860

New developments in immunotherapies for food allergy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698